We are thrilled to announce that Dr. Tomi Sawyer, a world leading Key Opinion Leader (KOL) in the field of peptide #drugdiscovery, will be joining the Pepticom Ltd. Scientific Board.

Tomi is renowned for the discovery of two FDA-approved drugs, including Scenesse®️ (marketed by Clinuvel) and Iclusig®️ (marketed by Takeda) as well as scientific contribution to the design of macrocyclic peptides, including ALRN-6924 (currently in Phase II clinical trials by Aileron Therapeutics).

Tomi has also been credited with ~600 scientific publications, patents, and presentations and holds several Adjunct Professorships and special appointments at the University of Massachusetts, Northeastern University Center for Drug Discovery, the University of Arizona, and Minnesota State University Moorhead. He has recently retired from a forty-year career in pharma/biotech, including Tomi’s last position at Merck Research Laboratories as Distinguished Scientist, Global #Chemistry, and leading the charge for the Peptide Drug Hunter network within R&D.

We are certain that Tomi’s vast expertise and recognition as a multidisciplinary drug hunter will further our mission to advance peptide #therapeutics utilizing our unique #biocomputational #AI software.

Happy 4th July and Welcome.